18/199 Deprescribing strategies for long-term use of benzodiazepines and z-drugs

Application dates: 29 November 2018 to 30 May 2019

The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this evidence synthesis topic:

18/199 Deprescribing strategies for long-term use of benzodiazepines and z-drugs

The UK NIHR and the Australian National Health and Medical Research Council (NHMRC) are collaborating on this research priority and will consider joint funding for any collaborative research proposals submitted to this brief. Applications which include a research collaboration between UK and Australian institutions are most welcome. Please refer to the supplementary guidance for additional requirements related to NIHR/NHMRC collaborative applications. Applications from UK institutions without an Australian collaborative element are also welcome for consideration.

The deadline for applications is 1pm, 30 May 2019.

Supporting information

*Please note: This document is to be used as a guide and to assist with completion of the on-line application form only, for example to see how many characters are accepted in each section and how the printed complete form is laid out. Please do not try to use this as an application form, you must apply using the online form available through the links available when calls are open. You should also refer to the application form guidance notes.

All primary research projects are expected to establish a programme appointed Study Steering Committee and it is important that you read the TSC/SSC Guidance before completing your application. Costs incurred by this committee should be included in the budget as appropriate.

Assessment dates

Applications received by the advertised closing date will be considered at a first-stage board, and successful applicants will then be invited to submit a stage 2 proposal. Applicants will have eight weeks to complete and submit a stage 2 application form, which will then be considered at the following HTA funding decision board. For more information, please read the commissioning brief.